Posted by Michael Wonder on 21 Apr 2022
Zambon receives U.S. FDA breakthrough therapy designation for CMS I-neb in patients with non-cystic fibrosis bronchiectasis
21 April 2022 - CMS I-neb is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonised with P. aeruginosa.
Zambon today announced that the U.S. FDA has granted breakthrough therapy designation to colistimethate sodium powder for nebulisation solution for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis colonised with P. aeruginosa.
